Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...
Purpose Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal ...
Objectives To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods This single-centre, prospective cohort study (January 2012 ...
Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...
Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific ...
Background Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, pregnancy ...
Pregnancy increases the risk of flare in patients with SLE and is associated with excess fetal morbidity and mortality.1 The ...
Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and left ventricular diastolic functions. This study aimed to evaluate the ...
Objectives Neuropsychiatric SLE (NPSLE) lacks evidence-based treatment strategies. This study compared the effectiveness and safety profiles of obinutuzumab (OBZ) and rituximab (RTX) in patients with ...
An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more likely to have adverse kidney outcomes and reduced response to therapy.1 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback